Processing...
Clinical Trials for Non-Small Cell Lung Cancer
Search
Search
There are 415 active trials for advanced/metastatic non-small cell lung cancer.
Click on a trial to see more information.
415 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with measurable, homozygous MTAP-deleted solid tumors and ECOG performance status 0–1 receive oral BAY 3713372, an investigational PRMT5 inhibitor designed to target the PRMT5–MTA complex. Expansion cohorts include non–small cell lung and pancreatic ductal adenocarcinomas and may test BAY 3713372 with unspecified combination partners.
ClinicalTrials.gov ID: NCT06914128
TrialFetch AI summary: Adults with previously treated metastatic or recurrent lung adenocarcinoma, a drainable malignant pleural effusion, and FRα expression in at least 10% of tumor cells receive cyclophosphamide/fludarabine lymphodepletion followed by a single intrapleural infusion of autologous MOv19-BBz CAR T cells. The CAR T cells target folate receptor alpha on tumor cells.
ClinicalTrials.gov ID: NCT07116057
TrialFetch AI summary: Adults with previously treated, advanced DLL3-expressing small-cell lung cancer are eligible; selected cohorts also include lung large-cell neuroendocrine carcinoma, neuroendocrine prostate cancer, and gastroenteropancreatic neuroendocrine carcinoma. All receive ²²⁵Ac-ETN029, a DLL3-binding peptide designed to deliver alpha radiation to tumors; some also receive ¹¹¹In-ETN029 for SPECT/CT imaging.
ClinicalTrials.gov ID: NCT07006727
TrialFetch AI summary: Adults with relapsed or refractory, locally advanced or metastatic solid tumors harboring a SMARCA4 loss-of-function mutation receive once-daily oral PLX-61639 after approved treatment options have been exhausted or deemed unsuitable. PLX-61639 is an investigational degrader that recruits DCAF16 to eliminate SMARCA2, a protein on which SMARCA4-deficient tumors may depend.
ClinicalTrials.gov ID: NCT07284186
TrialFetch AI summary: For patients with unresectable locally advanced or metastatic KRAS-mutated or KRAS-amplified solid tumors who have received, are ineligible for, or decline standard care, this study evaluates BMS-986523 alone or with pembrolizumab, cetuximab, or gemcitabine plus nab-paclitaxel. BMS-986523 is an investigational protein-degradation therapy with an undisclosed target; the pembrolizumab arm additionally requires PD-L1 expression ≥50%.
ClinicalTrials.gov ID: NCT07223047
TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors harboring any KRAS mutation or wild-type KRAS amplification receive intravenous PT0511, an investigational pan-KRAS protein degrader. A colorectal cancer expansion cohort receives PT0511 plus cetuximab, an anti-EGFR antibody.
ClinicalTrials.gov ID: NCT07300150
TrialFetch AI summary: Adults with unresectable, locally advanced or metastatic EGFR-mutated NSCLC that has progressed after first- or second-line osimertinib receive escalating doses of NXP900 plus osimertinib. NXP900 is an investigational oral inhibitor of SRC-family kinases, particularly YES1 and SRC.
ClinicalTrials.gov ID: NCT07315113
TrialFetch AI summary: Adults with advanced or unresectable solid tumors harboring ERBB2 alterations, NRG1 fusions, or HER2 overexpression receive oral CGT4255, an investigational HER2 inhibitor designed to target mutant and wild-type HER2 while sparing EGFR. Expansion cohorts focus on ERBB2-mutated NSCLC and ERBB2-mutated or HER2-overexpressing breast cancer, including patients with brain metastases.
ClinicalTrials.gov ID: NCT07361562
TrialFetch AI summary: Adults with locally advanced unresectable or metastatic urothelial carcinoma, NSCLC, gastric or gastroesophageal junction cancer, or HER2-negative breast cancer may be eligible, depending on cohort-specific prior therapy requirements. ASP2998, a TROP2-targeted antibody–drug conjugate carrying topoisomerase I inhibitor and STING agonist payloads, is given alone or with pembrolizumab, carboplatin, or enfortumab vedotin.
ClinicalTrials.gov ID: NCT07287995
TrialFetch AI summary: Adults with progressing relapsed or refractory, locally advanced inoperable or metastatic CRPC, colorectal, lung, head and neck, gynecologic, triple-negative breast, or esophageal squamous cell cancer receive 177Lu-BetaBart in a single-arm dose-escalation and expansion study. This investigational lutetium-177–labeled antibody targets B7-H3 (CD276) to deliver radiation to tumors.
ClinicalTrials.gov ID: NCT07189871